Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial

Authors:

Abstract
No abstract available
Funding Information
  • Sanofi France
  • Cancer Prevention and Research Institute of Texas (RP#180712)
  • Breast Cancer Research Foundation (BCRF-158)
  • Ligue Contre le Cancer
  • Pfizer France

This publication has 26 references indexed in Scilit: